The Longevity Industry is not just about biotechnology and biomedicine. Rather, it consists of several distinct segments: Geroscience, Biomedicine, AgeTech, and Finance. Despite this seemingly clear market segmentation, many of these sectors intersect with various domains of science and technology, such as advanced biomedicine, preventive medicine, digital health, AI, financial systems, pension systems, and government national strategies.
One of the biggest challenges in assessing the Longevity industry is the extreme broadness of the sector. Hundreds of sectors, industries, and domains of science and technology must be analyzed in order to obtain a concrete and comprehensive understanding of the dynamics, trends, and direction of the industry. This situation is entirely unique to the Longevity industry. Due to this extreme level of complexity, realistic assessment and forecasting is extremely challenging, and the methods currently being applied for assessment of the biotech and biomedical industries are completely inadequate.
The Longevity Industry has unprecedented levels of multidimensionality and intersectionality and unprecedented prospects for growth and profitability.
Currently, only the most advanced scientists work at the forefront of Longevity R&D. In the coming years, entrepreneurs and investors will gravitate to the Longevity industry when they realize its extreme potential for profitability and the fact that it is the most ethical form of business with the potential for the greatest positive impact for humanity.
The level of complexity also presents substantial risk given that it significantly complicates the ability of companies, investors, and even national governments to anticipate challenges (such as the risk of fraud) and recognize opportunities.
These challenges will be addressed in national Longevity development strategies that various nations are currently devising in response to the pressures of the looming Silver Tsunami.
Although challenges to realistic assessment and forecasting are great, they are not insurmountable. Established practices for forecasting and assessment already exist in other complex high-tech industries, and progress in big data analysis and AI for modeling can be adapted for use in Longevity. It is precisely this mission - the formulation of relevant, quantitative, analytical frameworks for Longevity industry assessment, benchmarking, forecasting and optimization - that has been a central component of the mission of Deep Knowledge Ventures and it’s Longevity-focused analytical subsidiary, Aging Analytics Agency, for the past several years.
This is the first in a series of articles on the Global Longevity Industry which will provide an overview of the scope and dynamics of this area, discuss current challenges and opportunities, and introduce new approaches to tangible and relevant assessment and forecasting.
No comments:
Post a Comment